Aktiesnakken — September 2013
-
jeg tror, at arzerra i første linie behandling vil være gamechanger for GEN - et fast cashflow vil give en helt anden basis for valuation
-
hvis man skal være lidt fræk, så kan man sige, at sidste gang vi fik en kurspåvirkende nyhed i GEN var helt tilbage til dara 30 aug 2012
-
CLL first line er stadig i limbo - rent meddelelsesmæssigt
-
...så det må være på tide, at vi får mere at vide. Jeg er i hvert fald nysgerrig på mere
-
men GEN ligger på 17 pladsen - så de skal overhales af hele 4 selskaber for at ryge ud...
-
Den tid, den sorg...
-
enig JV
-
rundt omkring på pladsen
-
nasdaq omx har det
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind